Q-omics provides the consensus-scored CLP1 profile across patient tissues and cancer cell-line models. CLP1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CLP1 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, CLP1 protein abundance shows 22,607 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, HNSC, and LSCC as cancer lineages where CLP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CLP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CLP1 survival associations across molecular data types. CLP1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CLP1 RNA expression–survival associations across cancer types. High CLP1 expression shows unfavorable associations in LGG, KICH and CESC, but favorable associations in KIRC, SCLC and READ. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CLP1 RNA expression.
This table summarizes CLP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for CLP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CLP1 shows lower tumor expression in THCA and higher tumor expression in HNSC, KIRC, LIHC, COAD and LUSC. The HNSC box plot shows higher CLP1 RNA expression in tumor versus normal tissue (log2 FC = +0.781, t-test p < 0.001).
This table shows molecular features associated with CLP1 in patient tissues and cancer cell lines. In patient samples, CLP1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CLP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
